GlassScriptPhysician profile
Hui Ying Hou
NPI 1184911687
$5,512.71
in general payments reported to CMS, 2019-2025
28 companies · $219 in 2025
The $219 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $393 · 2020: $143 · 2021: $407 · 2022: $806 · 2023: $3,302 · 2024: $242 · 2025: $219.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $2,209 · Food and Beverage: $1,478 · Education: $53.40 · Gift: $22.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $2,209.34 |
| Food and Beverage | $1,478.07 |
| Education | $53.40 |
| Gift | $22.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $2,902.80 | 2022-2023 | Da Vinci Surgical System |
| Abbvie INC. | $634.78 | 2019-2023 | |
| Exeltis, USA INC. | $218.26 | 2019-2025 | Slynd |
| Myriad Women'S Health, INC. | $143.86 | 2023 | Myrisk |
| Scynexis, INC. | $139.73 | 2021-2022 | |
| Millicent US INC | $132.82 | 2019-2025 | Femlyv, Femring, Intrarosa |
| Medtronic, INC. | $131.09 | 2021-2023 | Truclear |
| Agile Therapeutics, INC. | $124.85 | 2022-2024 | Twirla |
| Evofem Biosciences, INC. | $122.77 | 2021-2025 | Phexxi, Solosec, Phexx |
| Mayne Pharma Commercial LLC | $98.99 | 2021-2025 | |
| Daiichi Sankyo INC. | $97.40 | 2020-2022 | |
| Astellas Pharma US INC | $83.29 | 2024-2025 | Veozah |
| Myovant Sciences INC. | $77.64 | 2021-2022 | |
| Organon LLC | $73.47 | 2023-2025 | Nexplanon |
| Therapeuticsmd, INC. | $71.65 | 2019-2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $70.42 | 2023-2024 | |
| Sumitomo Pharma America, INC. | $57.29 | 2023-2025 | Myfembree |
| Hologic Sales and Service, LLC | $55.48 | 2021-2024 | Acessa Provu System |
| Avion Pharmaceuticals | $47.83 | 2020-2022 | |
| Lupin INC. | $44.58 | 2020-2021 | |
| Amag Pharmaceuticals, INC. | $38.69 | 2019 | |
| Merck Sharp & Dohme LLC | $29.83 | 2019-2021 | |
| Shield Therapeutics INC | $25.89 | 2022 | |
| Dexcom, INC. | $25.40 | 2025 | Dexcom G6 Transmitter |
| Dysis Medical, INC. | $20.65 | 2022 | |
| Mission Pharmacal Company | $15.96 | 2021 | |
| Gilead Sciences, INC. | $14.94 | 2019 | |
| Coopersurgical, INC. | $12.35 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hui Ying Hou listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.